Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China

Wu, Bin; Chen, Huafeng; Jin-fang, Shen; Ye, Ming

doi:10.1016/j.clinthera.2011.09.016

Cited by 48 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the R software package (version 2.13.0; R Development Core Team, Vienna, Austria), we used a previously developed Markov model to simulate the transition of a cohort of individuals with mRCC based on the clinical course [20]. We used this model to estimate and compare the lifetime direct medical costs and health outcomes associated with different first-line strategies for mRCC from the perspective of the Chinese healthcare system.…”

Section: Methodsmentioning

confidence: 99%

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting

Dong

Xu³

et al. 2012

PLoS ONE

Self Cite

View full text Add to dashboard Cite

BackgroundTo estimate, from the perspective of the Chinese healthcare system, the economic outcomes of five different first-line strategies among patients with metastatic renal cell carcinoma (mRCC).Methods and FindingsA decision-analytic model was developed to simulate the lifetime disease course associated with renal cell carcinoma. The health and economic outcomes of five first-line strategies (interferon-alfa, interleukin-2, interleukin-2 plus interferon-alfa, sunitinib and bevacizumab plus interferon-alfa) were estimated and assessed by indirect comparison. The clinical and utility data were taken from published studies. The cost data were estimated from local charge data and current Chinese practices. Sensitivity analyses were used to explore the impact of uncertainty regarding the results. The impact of the sunitinib patient assistant program (SPAP) was evaluated via scenario analysis. The base-case analysis showed that the sunitinib strategy yielded the maximum health benefits: 2.71 life years and 1.40 quality-adjusted life-years (QALY). The marginal cost-effectiveness (cost per additional QALY) gained via the sunitinib strategy compared with the conventional strategy was $220,384 (without SPAP, interleukin-2 plus interferon-alfa and bevacizumab plus interferon-alfa were dominated) and $16,993 (with SPAP, interferon-alfa, interleukin-2 plus interferon-alfa and bevacizumab plus interferon-alfa were dominated). In general, the results were sensitive to the hazard ratio of progression-free survival. The probabilistic sensitivity analysis demonstrated that the sunitinib strategy with SPAP was the most cost-effective approach when the willingness-to-pay threshold was over $16,000.ConclusionsOur analysis suggests that traditional cytokine therapy is the cost-effective option in the Chinese healthcare setting. In some relatively developed regions, sunitinib with SPAP may be a favorable cost-effective alternative for mRCC.

show abstract

Section: Methodsmentioning

confidence: 99%

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting

Dong

Xu³

et al. 2012

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Chinese govern ment has constructed a specific insurance system to provide up to approximately US$32,000 per year for patients with a catastrophic disease, such as advanced cancer [20][21][22]. Due to the lack of a specific threshold for Chinese patients with cancer, the cur- HR of survival of chemotherapy versus supportive care 0.77 (0.83-0.71) [24] Probability of progressed survival per cycle 0.086 (0.08-0.093) [25] ALK prevalence 0.065 (0.014-0.116) [9] Body surface (m 2 ) 1.72 (1.5-1.9) [26] Ventana IHC testing: …”

Section: Analytical Overview and Model Structurementioning

confidence: 99%

Economic Analysis of ALK Testing and Crizotinib Therapy for Advanced Non-Small-Cell Lung Cancer

Lü

Zhang

et al. 2016

Pharmacogenomics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both animal model and in vitro studies suggest that endostatin has anti-angiogenic effects [9–11]. Recombinant endostatin is being investigated as a therapy for a number of neoplastic tumours [12]. …”

Section: Introductionmentioning

confidence: 99%

Serum Endostatin Concentrations Are Higher in Men with Symptoms of Intermittent Claudication

et al. 2014

View full text Add to dashboard Cite

Objectives. A cleavage fragment of collagen XVIII, endostatin, is released into the circulation and has been demonstrated to have antiangiogenic effects in animal models. We hypothesized that circulating endostatin would be increased in patients with symptoms of lower limb peripheral artery disease. Design. Cross-sectional study. Participants. Community dwelling older men. Measurements. Intermittent claudication was defined using the Edinburgh Claudication Questionnaire (ECQ). Serum endostatin was measured by a commercial ELISA. The association of serum endostatin with intermittent claudication was examined using logistic regression adjusting for age, diabetes, hypertension, dyslipidemia, coronary heart disease, and stroke. Results. Serum endostatin was measured in 1114 men who completed the ECQ. 106 men had intermittent claudication, 291 had atypical pain, and 717 had no lower limb pain. Mean (±standard deviation) serum endostatin concentrations (ng/mL) were 145.22 ± 106.93 for men with intermittent claudication, 129.11 ± 79.80 for men with atypical pain, and 116.34 ± 66.57 for men with no lower limb pain; P < 0.001. A 70 ng/mL increase in endostatin was associated with a 1.17-fold rise in the adjusted odds of having intermittent claudication (OR 1.17, 95% confidence interval 1.00–1.37, and P = 0.050). Conclusions. Serum endostatin is raised in older men who have symptoms of intermittent claudication. The role of endostatin in the genesis and outcome of peripheral artery disease requires further investigation.

show abstract

Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China

Cited by 48 publications

References 18 publications

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting

Economic Analysis of ALK Testing and Crizotinib Therapy for Advanced Non-Small-Cell Lung Cancer

Serum Endostatin Concentrations Are Higher in Men with Symptoms of Intermittent Claudication

Contact Info

Product

Resources

About